海目星(688559.SH):江蘇海目星中標10.67億元Topcon激光微損設備招標項目
格隆匯4月15日丨海目星(688559.SH)公佈,公司全資子公司江蘇海目星於2022年4月15日收到晶科能源股份有限公司的中標通知書,中標金額10.67億元(具體金額以正式簽訂的設備採購合同為準)。項目名稱:Topcon激光微損設備招標項目。
本項目是公司光伏激光及自動化設備首次獲得大規模訂單,進一步體現了公司在激光及自動化裝備領域的行業地位及綜合競爭優勢,為公司進軍光伏專用設備領域奠定了良好的基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.